Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension
Authors:
- David CalhounDCDavid Calhoun
- Brent EganBEBrent Egan
- Christopher HellmannCHChristopher Hellmann
- Michael DolkerMDMichael Dolker
- Iris KingmaIKIris Kingma
- 1 November 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 20 (11) , 2257-2267
Abstract
To investigate the hypothesis that weight reduction with orlistat plus mild caloric restriction leads to better blood pressure control than diet alone in obese individuals with inadequately controlled hypertension. This was a 1-year, prospective, randomized, double-blind, placebo-controlled, multicenter trial of orlistat plus diet versus placebo plus diet in obese hypertensives. Participants were randomized to receive either orlistat or placebo; all received a 600 kcal deficient diet with no more than 30% of calories from fat. Weight and blood pressure, lipid levels and fasting glucose and insulin levels were followed. Patients on orlistat experienced greater weight loss (−5.4 ± 6.4 versus −2.7 ± 6.4 kg, P < 0.001) and greater reduction in body mass index (−1.9 ± 2.3 versus −0.9 ± 2.2 kg/m2, P < 0.001). Target weight loss, defined as ≥ 5% body weight (BW), was obtained in more orlistat-treated patients than in the placebo group (46 versus 23%, P < 0.001). Diastolic BP decreased more in orlistat-treated patients than in the placebo group (−11.4 ± 8.3 versus −9.2 ± 8.4 mmHg, P = 0.002). A greater percentage of orlistat-treated patients reached goal diastolic blood pressure (BP), defined as final diastolic BP < 90 mmHg or a reduction of at least 10 mmHg (67 versus 53%, P < 0.001). The orlistat-treated group had significantly greater reductions in total cholesterol (P < 0.001), low-density lipoprotein cholesterol (P = 0.001) and non-high-density lipoprotein cholesterol (P < 0.005) and target 30% cardiovascular risk reduction was obtained in more orlistat-treated patients (36.1 versus 24.0%, P < 0.04). A weight-loss program with orlistat is more effective than diet alone to lower blood pressure and results in greater cardiovascular risk reduction.Keywords
This publication has 69 references indexed in Scilit:
- Overweight and HypertensionHypertension, 2000
- Insulin and Diastolic Dysfunction in Lean and Obese HypertensivesHypertension, 1999
- Angiotensinogen levels and obesity in four black populationsJournal Of Hypertension, 1998
- SibutramineDrugs, 1998
- Overweight and obesity in the United States: prevalence and trends, 1960–1994International Journal of Obesity, 1997
- A Double‐Blind Randomized Placebo‐Controlled Trial of SibutramineObesity Research, 1996
- A Prospective Study of Obesity and Risk of Coronary Heart Disease in WomenNew England Journal of Medicine, 1990
- Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert PanelArchives of internal medicine (1960), 1988
- The Effect of Weight Reduction on Blood Pressure, Plasma Renin Activity, and Plasma Aldosterone Levels in Obese PatientsNew England Journal of Medicine, 1981
- Effect of Weight Loss without Salt Restriction on the Reduction of Blood Pressure in Overweight Hypertensive PatientsNew England Journal of Medicine, 1978